SpringWorks Therapeutics, Inc. (SWTX) Operating Income (Loss) USD 2017 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
SpringWorks Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2017 to 2024.
  • SpringWorks Therapeutics, Inc. Operating Income (Loss) for the quarter ending March 31, 2024 was -$93.9 M, a 20.9% decline year-over-year.
  • SpringWorks Therapeutics, Inc. Operating Income (Loss) for the twelve months ending March 31, 2024 was -$359 M, a 21% decline year-over-year.
  • SpringWorks Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$343 M, a 22.2% decline from 2022.
  • SpringWorks Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$281 M, a 61.8% decline from 2021.
  • SpringWorks Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$173 M, a 274% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$359 M -$93.9 M -$16.2 M -20.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 -$343 M -$98.5 M -$20 M -25.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 -$323 M -$84 M -$12.3 M -17.1% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 -$311 M -$82.9 M -$13.8 M -20.1% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-02
Q1 2023 -$297 M -$77.7 M -$16.2 M -26.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 -$281 M -$78.5 M -$22.7 M -40.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 -$258 M -$71.7 M -$30.8 M -75.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$227 M -$69 M -$22 M -46.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 -$205 M -$61.5 M -$31.7 M -107% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 -$173 M -$55.8 M -$67 M -597% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 -$106 M -$40.9 M -$19.3 M -89.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$87.2 M -$47 M -$27.2 M -137% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$60 M -$29.8 M -$13.6 M -84.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$46.3 M $11.2 M +$28.6 M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 -$74.9 M -$21.6 M -$6.26 M -40.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$68.7 M -$19.8 M -$4.97 M -33.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 -$63.7 M -$16.1 M -$4.44 M -38% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 -$59.2 M -$17.4 M -$10.9 M -169% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-12
Q3 2019 -$48.3 M -$15.3 M -$10.1 M -193% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$38.2 M -$14.9 M -$10.6 M -252% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-12
Q1 2019 -$27.6 M -$11.7 M -$9.1 M -351% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 -$18.5 M -$6.45 M -$1.79 M -38.4% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$16.7 M -$5.23 M Jul 1, 2018 Sep 30, 2018 10-K 2020-03-12
Q2 2018 -$4.22 M Apr 1, 2018 Jun 30, 2018 10-K 2020-03-12
Q1 2018 -$2.59 M Jan 1, 2018 Mar 31, 2018 10-K 2020-03-12
Q4 2017 -$4.66 M Aug 18, 2017 Dec 31, 2017 10-K 2020-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.